Current Products

Summary of Product Characteristics (SPC)

Patient Information Leaflet (PIL)

Risk Minimisation

Risk Minimisation materials (e.g. educational brochures, patient alert cards, posters etc) are intended to improve the use of a medicine by positively influencing health professionals and patients to reduce the risk and/or the severity of adverse reactions associated with a particular medicine.

These materials are additional to the medicine’s Summary of Product Characteristics and Patient Information Leaflet and their requirements are part of the product EU Risk Management Plan.

Only some medicines have a set of tailored risk minimisation materials developed for this purpose.
If required, these materials are reviewed and approved by the Medicines and Healthcare products Regulatory agency.

To access Risk Minimisation materials for our medicines, please click the following links: Please note that you will need to then click on the ‘Risk Materials’ banner at the top.

When you click one of the hyperlinks below you will be moving away from a BMS website to a website for which BMS has no responsibility. 

Yervoy (ipilimumab)

Eliquis (apixaban) (5mg) (2.5mg)

Perfalgan (paracetamol)


(▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Healthcare professionals and patients are asked to report any suspected side effects via the Yellow Card Scheme at Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or

Date of preparation: May 2016 466UK1500897-01